Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.

摘要: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are first-choice treatments for advanced non-small-cell lung cancer patients harboring EGFR mutations. Although mutations strongly predictive of patients' outcomes and their response to treatment with EGFR-TKIs, early failure first-line therapy EGFR-TKIs in is not rare. Besides several clinical factors influencing EGFR-TKI efficacies studied earlier such as the Eastern Cooperative Oncology Group performance status or uncommon mutation, we would like see whether semi-quantify mutation gene expression calculated by 2-ΔΔct was a prognostic EGFR-mutant non-small cell receiving EGFR-TKIs. This retrospective study reviews 926 diagnosed from January 2011 October 2013 at Kaohsiung Chang Gung Memorial Hospital Taiwan. Of 224 adenocarcinoma patients, 148 who had data were included. The best cutoff values in-frame deletions exon 19 (19 deletion) position 858 substituted leucine (L) an arginine (R) 21 (L858R) determined using receiver operating characteristic curves. Patients divided into high low based on above level. point value deletion L858R 31.1 104.7, respectively. In all, 92 (62.1%) showed 56 (37.9%) expression. mean age 65.6 years. Progression-free survival mutant versus level 17.07 12.04 months (P = 0.004), L858 13.75 7.96 0.008), lower longer progression-free duration without interfering overall survival.